Toll-like receptor 4 (TLR4) antibody, protein kinase B (AKT) inhibitor, LY 294002, and glycogen synthase kinase 3β (GSK-3β) inhibitor, LiCl, were used by Yu He and colleagues from Nantong University, ...
JUPITER, Fla. — Targeting a master-regulator of inflammation with a monoclonal antibody potentially improves two unrelated conditions that currently have limited treatment options: preterm births and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback